{"entity":{"id":"tovecimig","kind":"drug","name":"Tovecimig","aka":[],"tldr":"Tovecimig is an experimental bispecific antibody from Compass Therapeutics in phase 3 trials for biliary tract cancer and bladder & urothelial cancer, aimed at VEGF / VEGFR.","summary":"Tovecimig (CTX-009) is a bispecific antibody developed by Compass Therapeutics. Its target is VEGF / VEGFR (the sponsor names DLL4 x VEGF-A). The sponsor states: Simultaneously targets Delta-like ligand 4 (DLL4) and VEGF-A to inhibit tumour angiogenesis. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT05506943 (A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)), in biliary tract cancer and bladder & urothelial cancer. The largest, NCT05506943, plans to enrol 168 participants (actual) with primary completion expected 2027-08-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of Tovecimig","url":"https://clinicaltrials.gov/search?intr=Tovecimig"},{"label":"Sponsor pipeline page","url":"https://www.compasstherapeutics.com/pipeline"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma","urothelial"],"sections":[],"technologies":[],"targets":["vegf"],"drugs":[],"companies":["compass-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["companion-002"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"code":"CTX-009","modality":"bispecific antibody","mechanism":"Simultaneously targets Delta-like ligand 4 (DLL4) and VEGF-A to inhibit tumour angiogenesis.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tovecimig/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"target":[{"id":"dll4","kind":"target","name":"DLL4","route":"/targets/dll4/"},{"id":"vegf","kind":"target","name":"VEGF / VEGFR","route":"/targets/vegf/"}],"company":[{"id":"compass-therapeutics","kind":"company","name":"Compass Therapeutics","route":"/companies/compass-therapeutics/"}],"trial":[{"id":"companion-002","kind":"trial","name":"A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)","route":"/trials/companion-002/"},{"id":"nct07662031","kind":"trial","name":"Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer","route":"/trials/nct07662031/"}]}}